![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Neuropharm | LSE:NPH | London | Ordinary Share | GB00B1NPJJ01 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
| | | | | +---------------------------------------------+---------+---------+---------+ | Adjustments for: | | | | +---------------------------------------------+---------+---------+---------+ | Amortisation of intangible assets | - | 2 | 2 | +---------------------------------------------+---------+---------+---------+ | Impairment of intangibles assets | - | 40 | 40 | +---------------------------------------------+---------+---------+---------+ | Depreciation of property, plant and | 5 | 21 | 28 | | equipment | | | | +---------------------------------------------+---------+---------+---------+ | Impairment of property, plant and equipment | - | 149 | 149 | +---------------------------------------------+---------+---------+---------+ | Share option expense | 91 | 308 | 450 | +---------------------------------------------+---------+---------+---------+ | | | | | +---------------------------------------------+---------+---------+---------+ | Operating cash flows before movements in | (1,149) | (3,993) | (6,966) | | working capital | | | | +---------------------------------------------+---------+---------+---------+ | | | | | +---------------------------------------------+---------+---------+---------+ | Decrease in receivables | 13 | 342 | 446 | +---------------------------------------------+---------+---------+---------+ | Decrease in payables | (343) | (233) | (875) | +---------------------------------------------+---------+---------+---------+ | Increase in valuation of derivative | - | (148) | 2 | | financial investments | | | | +---------------------------------------------+---------+---------+---------+ | | | | | +---------------------------------------------+---------+---------+---------+ | Net cash used in operations | (1,479) | (4,032) | (7,393) | +---------------------------------------------+---------+---------+---------+ Cash and cash equivalents (which are presented as a single class of assets on the face of the balance sheet) comprise cash at bank and other short-term highly liquid investments with a maturity of three months or less. Independent review report to Neuropharm Group plc We have been engaged by the company to review the condensed set of financial statements in the half-yearly financial report for the six months ended 31 December 2009 which comprises the consolidated income statement, the consolidated statement of changes in equity, the consolidated balance sheet, the consolidated cash flow statement and related notes 1 to 8. We have read the other information contained in the half-yearly financial report and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements. This report is made solely to the company in accordance with International Standard on Review Engagements 2410 issued by the Auditing Practices Board. Our work has been undertaken so that we might state to the company those matters we are required to state to them in an independent review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company, for our review work, for this report, or for the conclusions we have formed. Directors' responsibilities The half-yearly financial report is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the half-yearly financial report in accordance with the AIM Rules of the London Stock Exchange As disclosed in note 2, the annual financial statements of the group are prepared in accordance with IFRS as adopted by the European Union. The condensed set of financial statements included in this half-yearly financial report have been prepared in accordance with the accounting policies the group intends to use in preparing its next annual financial statements. Our responsibility Our responsibility is to express to the Company a conclusion on the condensed set of financial statements in the half-yearly financial report based on our review. Scope of Review We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Auditing Practices Board for use in the United Kingdom. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK and Ireland) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Conclusion Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 31 December 2009 is not prepared, in all material respects, in accordance with the AIM Rules of the London Stock Exchange. Emphasis of matter - going concern Without qualifying our conclusion, we draw attention to the disclosures made under the heading "Going concern" in note 2 of the condensed financial statements which state, inter alia, that the Board has resolved to explore a return of cash to shareholders. If this return of cash were to be achieved by way of a Members Voluntary Liquidation ("MVL") then the going concern basis of preparation would no longer be appropriate. Therefore, whilst the Directors are satisfied that there is sufficient discretion and control as to the timing and quantum of cash outflows to ensure that the Group is able to meet its liabilities as they fall due for at least the next 12 months, the possibility of entering into a MVL indicates the existence of a material uncertainty which may cast significant doubt about the Group's ability to continue as a going concern. The interim report does not include the adjustments that would result if the Group's condensed financial statements were prepared on a basis other than going concern as it is not practicable to determine or quantify them. Deloitte LLP Chartered Accountants and Statutory Auditors Cambridge, United Kingdom 22 March 2010 This information is provided by RNS The company news service from the London Stock Exchange END IR LLLLLBXFFBBF
1 Year Neuropharm Chart |
1 Month Neuropharm Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions